TAIMED BIOLOGICS INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 83 TWD | +0.61% |
|
-0.12% | +1.22% |
ETFs positioned on TaiMed Biologics Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.11% | 2 M€ | -.--% | ||
| 0.04% | 7 M€ | -.--% | - | |
| 0.01% | 4 M€ | -4.41% | - | |
| 0.00% | 117 M€ | +1.11% | - | |
| 0.00% | 34 M€ | +2.14% | - |
TaiMed Biologics Inc. is a Taiwan-based company principally engaged in the research and development of new medicines. The Company mainly provides ibalizumab (TMB-355) and TMB-360, which are applied in the treatment of acquired immune deficiency syndrome (AIDS), and protease inhibitor (TMB-607), which is applied as pro-drugs for AIDS. The Company's ibalizumab is a humanized monoclonal antibody, which can interfere with the penetration of the virus into the cell. Its protease inhibitor uses nanotechnology formulation for subcutaneous and/or intramuscular injections.
Calendar
2024-05-09
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
83
TWD
Average target price
133.7
TWD
Spread / Average Target
+61.07%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +1.22% | 644M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- 4147 Stock
- Funds and ETFs TaiMed Biologics Inc.
